Abiraterone Decanoate Drug Asset Due Diligence Report 2026

This Abiraterone Decanoate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Abiraterone Decanoate can convert its Small molecule drug profile and CYP17A1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Abiraterone Decanoate (query alias: Abiraterone Decanoate)
Modality / target	Small molecule drug; CYP17A1; CYP17A1 inhibitors
Highest global status	Phase 2
Originator	Propella Therapeutics, Inc.
Active developers	Astellas Pharma Global Development, Inc., Astellas (China) Investment Co., Ltd., Astellas Pharma, Inc.

The MCP disease footprint includes Advanced Prostate Carcinoma, Castration-sensitive prostate cancer, Metastatic castration-resistant prostate cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07339267	Phase 1	Recruiting	12	Primary endpoint not disclosed in English source
NCT07005154	Phase 2	Recruiting	218	Primary endpoint not disclosed in English source
NCT04729114	Phase 1	Recruiting	174	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Phase 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate, in patients with prostate cancer including those previously treated with enzalutamide.

Phase 1/2; n=22; evaluation: Positive. Reported fields: DLT = 0 % ; DLT = 0 %

Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate in patients (pts) with advanced prostate cancer.

Phase 1/2; n=17; evaluation: Positive. Reported fields: RP2D = 1800 mg

1386P - 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114)

Phase 1; n=15; evaluation: Positive. Reported fields: CTCAE G2 events = Two CTCAE G2 events were considered possibly related to study drug: fatigue, loss of appetite

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Abiraterone Decanoate addresses Advanced Prostate Carcinoma, Castration-sensitive prostate cancer, Metastatic castration-resistant prostate cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-11-15	Astellas US Holding, Inc. acquires Propella Therapeutics, Inc.	Phase 1	US$175.0M stated total
2021-02-23	Propella Therapeutics Partners with National Cancer Institute to Develop New Treatment for Metastatic Prostate Cancer	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination of Anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor”. The milestone feed surfaced a patent-application signal described as “Abiraterone decanoate composition and use in therapy”. The milestone feed surfaced a patent-application signal described as “Abiraterone decanoate prodrugs and use in therapy”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO